| The streptozotocin-diabetic rat as a model of the chronic complications of human diabetes M Wei, L Ong, MT Smith, FB Ross, K Schmid, AJ Hoey, D Burstow, ... Heart, lung and circulation 12 (1), 44-50, 2003 | 430 | 2003 |
| Morphine-3-glucuronide-a potent antagonist of morphine analgesia MT Smith, JA Watt, T Cramond Life sciences 47 (6), 579-585, 1990 | 420 | 1990 |
| Neuroexcitatory effects of morphine and hydromorphone: evidence implicating the 3-glucuronide metabolites. MT Smith Clinical and experimental pharmacology & physiology 27 (7), 524-528, 2000 | 375 | 2000 |
| Bioerodable PLGA-based microparticles for producing sustained-release drug formulations and strategies for improving drug loading FY Han, KJ Thurecht, AK Whittaker, MT Smith Frontiers in pharmacology 7, 185, 2016 | 373 | 2016 |
| Pharmacokinetic changes in patients receiving extracorporeal membrane oxygenation K Shekar, JF Fraser, MT Smith, JA Roberts Journal of critical care 27 (6), 741. e9-741. e18, 2012 | 334 | 2012 |
| The pharmacokinetics of midazolam in man MT Smith, MJ Eadie, TOR Brophy European journal of clinical pharmacology 19, 271-278, 1981 | 318 | 1981 |
| Pathobiology of cancer chemotherapy-induced peripheral neuropathy (CIPN) Y Han, MT Smith Frontiers in pharmacology 4, 156, 2013 | 317 | 2013 |
| The intrinsic antinociceptive effects of oxycodone appear to be κ-opioid receptor mediated FB Ross, MT Smith Pain 73 (2), 151-157, 1997 | 307 | 1997 |
| Sequestration of drugs in the circuit may lead to therapeutic failure during extracorporeal membrane oxygenation K Shekar, JA Roberts, CI Mcdonald, S Fisquet, AG Barnett, DV Mullany, ... Critical care 16, 1-7, 2012 | 273 | 2012 |
| The novel N-type calcium channel blocker, AM336, produces potent dose-dependent antinociception after intrathecal dosing in rats and inhibits substance P release in rat spinal … MT Smith, PJ Cabot, FB Ross, AD Robertson, RJ Lewis Pain 96 (1), 119-127, 2002 | 232 | 2002 |
| Oxycodone and morphine have distinctly different pharmacological profiles: radioligand binding and behavioural studies in two rat models of neuropathic pain CK Nielsen, FB Ross, S Lotfipour, KS Saini, SR Edwards, MT Smith Pain 132 (3), 289-300, 2007 | 228 | 2007 |
| Neurotrophins and neuropathic pain: role in pathobiology N Khan, MT Smith Molecules 20 (6), 10657-10688, 2015 | 219 | 2015 |
| PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models BI Dredge K, Hammond E, Handley P, Gonda TJ, Smith MT, Vincent T, Brandt R ... Br J Cancer 104, 635-642, 2011 | 202 | 2011 |
| An update on the pharmacological management of post-herpetic neuralgia and painful diabetic neuropathy CS Zin, LM Nissen, MT Smith, JP O’Callaghan, BJ Moore CNS drugs 22, 417-442, 2008 | 178 | 2008 |
| Single‐dose and steady‐state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer KP Leow, MT Smith, B Williams, T Cramond Clinical Pharmacology & Therapeutics 52 (5), 487-495, 1992 | 172 | 1992 |
| Validating Eaton's hypothesis: Cubane as a benzene bioisostere BA Chalmers, H Xing, S Houston, C Clark, S Ghassabian, A Kuo, B Cao, ... Angewandte Chemie International Edition 55 (11), 3580-3585, 2016 | 155 | 2016 |
| Multiple sclerosis-induced neuropathic pain: pharmacological management and pathophysiological insights from rodent EAE models N Khan, MT Smith Inflammopharmacology 22, 1-22, 2014 | 155 | 2014 |
| Hydromorphone-3-glucuronide: a more potent neuro-excitant than its structural analogue, morphine-3-glucuronide AWE Wright, LE Mather, MT Smith Life sciences 69 (4), 409-420, 2001 | 154 | 2001 |
| Production of analgesic synergy by co-administration of sub-analgesic doses of a MU opioid agonist and a kappa-2 opioid agonist M Smith, F Ross US Patent 6,310,072, 2001 | 136 | 2001 |
| Anti-allodynic efficacy of the χ-conopeptide, Xen2174, in rats with neuropathic pain CK Nielsen, RJ Lewis, D Alewood, R Drinkwater, E Palant, M Patterson, ... Pain 118 (1-2), 112-124, 2005 | 135 | 2005 |
